BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27046391)

  • 1. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration.
    Beato J; Pedrosa AC; Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Melo A; Estrela-Silva S; Falcão-Reis F; Carneiro ÂM
    Ophthalmic Res; 2016; 56(1):30-4. PubMed ID: 27046391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
    Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
    Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.
    Nariani A; Williams B; Hariprasad SM
    Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.
    Yannuzzi NA; Patel SN; Bhavsar KV; Sugiguchi F; Freund KB
    Am J Ophthalmol; 2014 Aug; 158(2):319-327.e2. PubMed ID: 24814167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
    J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
    Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
    Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
    Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
    BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
    Adelman RA; Zheng Q; Mayer HR
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
    Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
    Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry.
    Atchison EA; Wood KM; Mattox CG; Barry CN; Lum F; MacCumber MW
    Ophthalmology; 2018 May; 125(5):676-682. PubMed ID: 29336897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scheduled versus Pro Re Nata Dosing in the VIEW Trials.
    Richard G; Monés J; Wolf S; Korobelnik JF; Guymer R; Goldstein M; Norenberg C; Sandbrink R; Zeitz O
    Ophthalmology; 2015 Dec; 122(12):2497-503. PubMed ID: 26477840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye.
    Abdelfattah NS; Zhang H; Boyer DS; Rosenfeld PJ; Feuer WJ; Gregori G; Sadda SR
    Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1839-46. PubMed ID: 27082298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration.
    Saleh R; Karpe A; Zinkernagel MS; Munk MR
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):817-824. PubMed ID: 28127658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Elevation of Intraocular Pressure After Administration of Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Patients With and Without Pseudoexfoliation Syndrome.
    Ucgul AY; Aktas Z; Ozgur A; Cubuk MO; Hasanreisoglu M; Ozdek S; Gurelik G
    J Glaucoma; 2020 Oct; 29(10):981-988. PubMed ID: 32649449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting.
    Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
    Frenkel MP; Haji SA; Frenkel RE
    Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.
    Arslan GD; Guven D; Alkan AA; Kacar H; Demir M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):344-348. PubMed ID: 31092017
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.
    Wen JC; Reina-Torres E; Sherwood JM; Challa P; Liu KC; Li G; Chang JY; Cousins SW; Schuman SG; Mettu PS; Stamer WD; Overby DR; Allingham RR
    Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1893-1898. PubMed ID: 28358961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.